Introduction: Gene therapy offers promising approaches for the development of anticancer
agents with new modes of action. Among gene therapy vectors, vaccinia virus has emerged …

Attenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens
are currently at various stages in clinical trials with the aim to establish their efficacy. This is …

The modified vaccinia virus Ankara (MVA) strain is a candidate vector for vaccination against
pathogens and tumors, due to safety concerns and the proven ability of recombinants based …

A heterologous prime-boost vaccination regime with DNA and recombinant vaccinia virus
(rVV) vectors expressing relevant antigens has been shown to enhance specific cellular …

Immunity to Trypanosoma cruzi requires elicitation of humoral and cell-mediated immune
responses to extracellular trypomastigotes and intracellular amastigotes. In this study, the …

Tumor directed gene therapy for the purpose of destroying cancer cells through replicative
“oncolysis” or by intratumoral expression of toxic or immunostimulatory genes requires an …

Vaccinia virus has played a huge part in human beings' victory over smallpox. With smallpox
being eradicated and large-scale vaccination stopped worldwide, vaccinia has assumed a …

The poxvirus strains NYVAC and MVA are two candidate vectors for the development of
vaccines against a broad spectrum of diseases. Although these attenuated virus strains …

Background The addition of plasmid cytokine adjuvants, electroporation, and live attenuated
viral vectors may further optimize immune responses to DNA vaccines in heterologous prime …

The majority of infections initiate their departure from a mucosal surface, such as Human
immunodeficiency virus (HIV), a sexually transmitted virus. Therefore, the induction of …